Introduction: Erlotinib was recently approved in British Columbia (BC) as a second-line
treatment for advanced NSCLC. A cost-effectiveness analysis was conducted which …

Erlotinib has been approved as a third-line treatment for advanced non-small-cell lung
cancer (NSCLC) in British Columbia (BC). A cost-effectiveness analysis was conducted to …

This study was designed to assess the cost-effectiveness of erlotinib compared with
docetaxel in the second-line management of advanced non-small-cell lung cancer (NSCLC) …

Treatment with third-generation chemotherapy agents improves survival and quality of life of
patients with non-small-cell lung cancer (NSCLC). Despite these favorable outcomes, most …

Background: The extent of the benefit of erlotinib in the treatment of advanced nonsmall-cell
lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …

Background: Erlotinib, docetaxel and pemetrexed are all approved in the second-line setting
for patients with advanced NSCLC who progress following first-line platinum doublet …

Objective of this indirect economic comparison was to estimate and compare management
costs of grade 3/4 adverse events (AEs) reported for first-line erlotinib or pemetrexed …

7664 Background: Multiple treatment strategies are now available for stage IIIB/IV non-small
cell lung cancer (NSCLC) after failure of 1st line treatment, but their relative economic and …

Background: Lung cancer is the leading cause of cancer deaths worldwide (1.38 million
cancer deaths, 18.2% of the total) and of cancer morbidity (1.61 million new cases, 12.7% of …

OBJECTIVE: A PE analysis was performed to support the reimbursement request of erlotinib
in 2nd/3rd-line treatment of NSCLC in The Netherlands (NL). METHODS: Erlotinib and BSC …